BiotechTube
eTheRNA immunotherapies

eTheRNA immunotherapies

Niel, Belgium· Est.
etherna.be
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $73M

Overview

eTheRNA immunotherapies is a platform-driven RNA-LNP technology company based in Niel, Belgium. It leverages decades of scientific expertise to offer integrated capabilities in RNA chemistry, LNP delivery technologies, and GMP manufacturing, supporting partners from discovery through clinical development. The company operates through a dual business model of technology/product partnering and is advancing its own clinical-stage pipeline, including an intratumoral oncology platform now in clinical testing with partner Almirall.

OncologyInfectious DiseasesImmunology

Technology Platform

Integrated proprietary platforms for mRNA sequence design/chemistry and customizable lipid nanoparticle (LNP) formulation for targeted nucleic acid delivery across multiple administration routes.

Funding History

2
Total raised:$73M
Series B$39M
Series A$34M

Opportunities

The validated success of mRNA vaccines has created immense demand for advanced LNP delivery technologies capable of targeting tissues beyond the liver.
eTheRNA's proven ability to design LNPs for extra-hepatic delivery (e.g., to bone marrow) positions it to capture partnership opportunities in high-value areas like cell therapy and regenerative medicine.
Furthermore, its integrated platform and European GMP manufacturing offer a compelling one-stop-shop for biotechs seeking to accelerate RNA therapeutic development.

Risk Factors

The company faces significant competition from established giants and well-funded startups in the RNA delivery space.
Its financial sustainability as a private entity depends on securing ongoing partnerships and funding to advance its costly internal pipeline.
Technological risk persists, as the long-term efficacy and safety profile of its novel LNP designs must be conclusively proven in late-stage human trials.

Competitive Landscape

eTheRNA competes in the crowded RNA therapeutics and LNP delivery space against large-cap biotechs like Moderna and BioNTech, lipid nanoparticle specialists such as Acuitas Therapeutics and Genevant Sciences, and numerous other platform companies. Its differentiation lies in its integrated RNA+LNP design approach, emphasis on customizable delivery for specific routes/indications, and its dual role as both a platform provider and a therapeutic developer with clinical-stage assets.

More companies in mRNA Therapeutics →More companies in Belgium →